Skip to main content

Her2 Positive Breast Cancer

In Order to Read Online or Download Her2 Positive Breast Cancer Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

HER2 Positive Breast Cancer

HER2 Positive Breast Cancer Book
Author : Sara Hurvitz,Kelly McCann
Publisher : Elsevier Health Sciences
Release : 2018-07-26
ISBN : 0323581234
Language : En, Es, Fr & De

GET BOOK

Book Description :

Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

Handbook of HER2 Targeted Agents in Breast Cancer

Handbook of HER2 Targeted Agents in Breast Cancer Book
Author : Ricardo H Alvarez,Javier Cortés,Mary Falzon,Michael Gandy,Luca Gianni,Nadia Harbeck,Martine Piccart
Publisher : Springer
Release : 2016-05-14
ISBN : 3319282166
Language : En, Es, Fr & De

GET BOOK

Book Description :

This concise handbook provides oncologists and other healthcare providers with crucial updates in the field, including an updated review of the current understanding of the biology of the HER2 pathway, an overview of HER2-testing, and evidence-based discussions of available and emerging HER2-targeted treatment options. An essential clinical text for physicians that screen and treat patients with breast cancer and require an accessible, up-to-date survey of the dynamic treatment landscape.

Treatment of HER2 positive Breast Cancer

Treatment of HER2 positive Breast Cancer Book
Author : Simona Borštnar
Publisher : Unknown
Release : 2015
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Treatment of HER2 positive Breast Cancer book written by Simona Borštnar, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Mechanisms of Resistance to Lapatinib in HER2 Positive Breast Cancer

Mechanisms of Resistance to Lapatinib in HER2 Positive Breast Cancer Book
Author : Martina McDermott
Publisher : Unknown
Release : 2012
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Mechanisms of Resistance to Lapatinib in HER2 Positive Breast Cancer book written by Martina McDermott, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Metabolomic Analysis of HER2 positive Breast Cancer Cells

Metabolomic Analysis of HER2 positive Breast Cancer Cells Book
Author : Malika Kaur Sahni,California State University, Fresno. Department of Biology
Publisher : Unknown
Release : 2014
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Metabolomic Analysis of HER2 positive Breast Cancer Cells book written by Malika Kaur Sahni,California State University, Fresno. Department of Biology, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Biological Signature of HER2 positive Breast Cancer

Biological Signature of HER2 positive Breast Cancer Book
Author : Anonim
Publisher : Unknown
Release : 2013
ISBN : 9789176689417
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Biological Signature of HER2 positive Breast Cancer book written by , available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Mechanisms of Resistance to T DM1 in HER2 positive Breast Cancer

Mechanisms of Resistance to T DM1 in HER2 positive Breast Cancer Book
Author : Junjie Zhang
Publisher : Unknown
Release : 2018
ISBN : 9788449080326
Language : En, Es, Fr & De

GET BOOK

Book Description :

El cáncer de mama HER2-positivo representa alrededor del 15-30% del total de pacientes con cáncer de mama. Este subtipo tiene un mal pronóstico, seguido del subtipo Triple-negativo (TNBC), que lo tiene aún peor. Actualmente, varios medicamentos están aprobados para las pacientes HER2-positivo, como Trastuzumab, Lapatinib y T-DM1. Sin embargo, a menudo éstas adquieren resistencia a estas terapias en un período de 1 a 2 años. El objetivo principal de este estudio es definir los mecanismos de resistencia a T-DM1. Durante mi tesis, generé líneas celulares resistentes a T-DM1 y exploré diferentes posibilidades in vitro que pudieran explicar cómo estas células escapan de la terapia contra HER2. Obtuve células resistentes a T-DM1 usando una línea celular derivada de un tumor primario de una paciente (PDX, Patient-derived xenograft) tratándolas con dosis crecientes de T-DM1. Comprobé los niveles de HER2 por mRNA y proteína, número de copias, efectores de señalización, analicé la región citotóxica de T-DM1 y su actividad lisosómica diferencial comparando la línea parental y las células resistentes. Esta tesis describe punto por punto todos los posibles mecanismos de resistencia que investigamos y cuales resultaron ser los responsables de la resistencia a T-DM1.

Targeting Telomerase in HER2 Positive Breast Cancer

Targeting Telomerase in HER2 Positive Breast Cancer Book
Author : Jillian Elizabeth Koziel
Publisher : Unknown
Release : 2015
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Cancer stem cells (CSCs) are proposed to play a major role in tumor progression, metastasis, and recurrence. The Human Epidermal growth factor Receptor 2 (HER2) gene is amplified and/or its protein product overexpressed in approximately 20% of breast cancers. HER2 overexpression is associated with increased CSCs, which may explain the aggressive phenotype and increased likelihood of recurrence for HER2+ breast cancers. Telomerase is reactivated in tumor cells, including CSCs, but has limited activity in normal tissues, providing support for the use of telomerase inhibition in anti-cancer therapy. Telomerase inhibition via an antagonistic oligonucleotide, imetelstat (GRN163L), has been shown to be effective in limiting cell growth in vitro and limiting tumor growth. Moreover, we have previously shown imetelstat can decrease metastases to the lungs, leading us to question if this is due to imetelstat targeting the CSC population. In this thesis, we investigated the effects of imetelstat on CSC and non-CSC populations of HER2+ breast cancer cell lines, as well as a triple negative breast cancer cell line, which lacks HER2 overexpression. Imetelstat inhibited telomerase activity in both CSC and non-CSC subpopulations. Moreover, imetelstat treatment alone and in combination with trastuzumab significantly reduced the CSC fraction and inhibited CSC functional ability, as shown by a significant decrease in mammosphere counts and invasive potential. Tumor growth rate was slower in combination treated mice compared to either drug alone. Additionally, there was a trend toward decreased CSC marker expression in imetelstat treated xenograft cells compared to vehicle control. The decrease in CSC marker expression we observed occurred prior to and after telomere shortening, suggesting imetelstat acts on the CSC subpopulation in telomere length dependent and independent mechanisms. Our study suggests addition of imetelstat to trastuzumab may enhance the effects of HER2 inhibition therapy.

Resistance to HER2 targeted Therapies in HER2 positive Breast Cancer

Resistance to HER2 targeted Therapies in HER2 positive Breast Cancer Book
Author : Natasha Tracey
Publisher : Unknown
Release : 2019
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Resistance to HER2 targeted Therapies in HER2 positive Breast Cancer book written by Natasha Tracey, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

HER2 Testing to Manage Patients with Breast Cancer and Other Solid Tumors

HER2 Testing to Manage Patients with Breast Cancer and Other Solid Tumors Book
Author : U. S. Department of Health and Human Services,Agency for Healthcare Research and Quality
Publisher : Createspace Independent Pub
Release : 2013-05-31
ISBN : 9781490324173
Language : En, Es, Fr & De

GET BOOK

Book Description :

The human epidermal growth factor receptor-2 (HER2) gene is amplified and the HER2 protein overexpressed in approximately 18–20 percent of breast cancer cases. Amplification or overexpression of HER2 is associated with poor prognosis. Evidence from randomized trials demonstrates that adding trastuzumab, a therapeutic monoclonal antibody that targets HER2, to adjuvant chemotherapy regimens for HER2-positive breast cancer improves survival. HER2 also is overexpressed in other epithelial malignancies such as ovarian, thyroid, lung, salivary gland/head and neck, stomach, colon, and prostate cancers. This report is a systematic review of the evidence on other applications of HER2 testing to the management of cancer patients including: potential for response to trastuzumab among breast cancer patients who have negative, equivocal, or discordant HER2 assay results; use of HER2 assay results to guide selection of breast cancer treatments other than trastuzumab (i.e., chemotherapy regimen or hormonal therapy regimen); the use of serum HER2 to monitor treatment response or disease progression in breast cancer patients; and use of HER2 testing to manage patients with ovarian, lung, prostate, or head and neck tumors. The concordance and discrepancy of HER2 measurement methods are discussed in a narrative review. This systematic review will address five key questions regarding HER2 testing to manage patients with breast cancer or other solid tumors: What is the evidence on concordance and discrepancy rates for methods (e.g., FISH, IHC, etc.) used to analyze HER2 status in breast tumor tissue? 2. For patients who are not unequivocally HER2 positive, what is the evidence on outcomes of treatment targeting the HER2 molecule (trastuzumab, etc.), or on differences in outcomes of a common chemotherapy or hormonal therapy regimen with versus without additional treatment targeting the HER2 molecule, in: a) Breast cancer patients characterized by discrepant HER2 results from different tissue assay methods performed adequately; and b) For those with HER2-negative breast cancer? 3. For breast cancer patients, what is the evidence on clinical benefits and harms of using HER2 assay results to guide selection of: a) Chemotherapy regimen; or b) Hormonal therapy? 4. What is the evidence that monitoring serum or plasma concentrations of HER2 extracellular domain in patients with HER2-positive breast cancer predicts response to therapy, or detects tumor progression or recurrence, and if so, what is the evidence that decisions based on serum or plasma HER2 assay results improve patient management and outcomes? 5. In patients with ovarian, lung, prostate, or head and neck cancers, what is the evidence that: a) Testing tumor tissue for HER2; or b) Monitoring serum or plasma concentrations of HER2; either predicts response to therapy, or detects tumor progression or recurrence; and if so, what is the evidence that decisions based on HER2 assay results improve patient management and outcomes?

Gut Microbiota and Trastuzumab Response in HER2 positive Breast Cancer

Gut Microbiota and Trastuzumab Response in HER2 positive Breast Cancer Book
Author : Martina Di Modica
Publisher : Unknown
Release : 2020
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Gut Microbiota and Trastuzumab Response in HER2 positive Breast Cancer book written by Martina Di Modica, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

BAG 1 Expression and Function in HER2 positive Breast Cancer

BAG 1 Expression and Function in HER2 positive Breast Cancer Book
Author : Natalia Robson
Publisher : Unknown
Release : 2016
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download BAG 1 Expression and Function in HER2 positive Breast Cancer book written by Natalia Robson, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

HER2 Inhibitors Advances in Research and Application 2012 Edition

HER2 Inhibitors   Advances in Research and Application  2012 Edition Book
Author : Anonim
Publisher : ScholarlyEditions
Release : 2012-12-26
ISBN : 1481609874
Language : En, Es, Fr & De

GET BOOK

Book Description :

HER2 Inhibitors—Advances in Research and Application: 2012 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about HER2 Inhibitors in a concise format. The editors have built HER2 Inhibitors—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about HER2 Inhibitors in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of HER2 Inhibitors—Advances in Research and Application: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

HER2 Inhibitors Advances in Research and Application 2013 Edition

HER2 Inhibitors   Advances in Research and Application  2013 Edition Book
Author : Anonim
Publisher : ScholarlyEditions
Release : 2013-06-21
ISBN : 1481676237
Language : En, Es, Fr & De

GET BOOK

Book Description :

HER2 Inhibitors—Advances in Research and Application: 2013 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about ZZZAdditional Research in a concise format. The editors have built HER2 Inhibitors—Advances in Research and Application: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about ZZZAdditional Research in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of HER2 Inhibitors—Advances in Research and Application: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Evaluation of RAF Kinase Polymorphisms in HER2 positive Breast Cancer Patients

Evaluation of RAF Kinase Polymorphisms in HER2 positive Breast Cancer Patients Book
Author : Lan Phuong Pham Tran
Publisher : Unknown
Release : 2008
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Evaluation of RAF Kinase Polymorphisms in HER2 positive Breast Cancer Patients book written by Lan Phuong Pham Tran, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Trastuzumab for the Adjuvant Treatment of Early stage HER2 positive Breast Cancer

Trastuzumab for the Adjuvant Treatment of Early stage HER2 positive Breast Cancer Book
Author : National Institute for Health and Clinical Excellence (Great Britain)
Publisher : Unknown
Release : 2006
ISBN : 9781846292811
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Trastuzumab for the Adjuvant Treatment of Early stage HER2 positive Breast Cancer book written by National Institute for Health and Clinical Excellence (Great Britain), available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Analysis of Organotropic Metastasis in Relation to Herceptin Response of HER2 Positive Breast Cancer Cells

Analysis of Organotropic Metastasis in Relation to Herceptin Response of HER2 Positive Breast Cancer Cells Book
Author : Justin Molnar
Publisher : Unknown
Release : 2017
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

HER2 (Epidermal Growth Factor Receptor Type 2) positive breast cancer accounts for 20-30 percent of cases and is associated with increased tumor cell proliferation, resistance to hormonal therapies and decreased patient survival. Trastuzumab (Herceptin®, Genentech-Roche) induces cytotoxicity in HER2+ breast cancer, significantly increases patient survival and is one of only a few targeted therapies approved for this aggressive malignancy. However, the majority of patients that qualify for this line of therapy exhibit innate or acquired resistance and must stop treatment. Herceptin resistance is associated with increased incidence of local invasion and systemic metastasis, and there is a need for in vivo methods to study the metastatic potential of Herceptin resistant and sensitive HER2+ breast cancer cells. Here, we have used the chicken (Gallus gallus) embryo chorioallantoic membrane (CAM) to establish an in vivo model of spontaneous metastasis for evaluating organotropism in Herceptin sensitive (SKBR3 and BT474) and resistant (AU565/innate and BT474-HR6/acquired) HER2+ breast cancer cells. Importantly, we demonstrate for the first time that Herceptin resistant cells are significantly more metastatic than their sensitive counterparts. We confirmed these results in vitro using 4D confocal microscopy and demonstrate that Herceptin resistant cells are also more invasive. Most notably, we report significant differences in the organotropisms for HER2+ breast cancer cells with innate versus acquired Herceptin resistance. Innately resistant cells exhibit significant increases in pulmotropic and hepatotropic metastases consistent with their increased expression of KRT81 and ID1. Alternatively, cells with acquired resistance exhibit significant increases in neurotropic metastasis consistent with their increased expression of HBEGF. Interestingly, cancer-associated fibroblasts (CAFs) derived from HER2+ breast cancer patients have been previously reported to also express elevated levels of HBEGF, suggesting that HER2+ CAFs may potentiate Herceptin resistance and neurotropic metastasis. To evaluate the role of stromal fibroblasts on HER2+ breast cancer cell organotropism, we first co-xenografted embryonic fibroblasts together with HER2+ breast cancer cells into the CAM model - we observed selective prometastatic effects of these stromal fibroblasts only on Herceptin resistant cells. We propose that this novel co-xenografting in vivo model can be used to evaluate the regulatory effects of patient-derived CAFs on organotropism of HER2+ breast cancer cells in relation to their Herceptin responsiveness. Findings from these studies will illuminate the cellular and molecular mechanisms that drive organotropism in aggressive and therapy-refractory breast cancers.

Delineating Early Transformational Events in HER2 Positive Breast Cancer Using an Inducible MCF10A Cell Line

Delineating Early Transformational Events in HER2 Positive Breast Cancer Using an Inducible MCF10A Cell Line Book
Author : Ateequllah Hayat
Publisher : Unknown
Release : 2020
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Delineating Early Transformational Events in HER2 Positive Breast Cancer Using an Inducible MCF10A Cell Line book written by Ateequllah Hayat, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development Book
Author : null Hasmann
Publisher : Elsevier Inc. Chapters
Release : 2013-05-07
ISBN : 0128061995
Language : En, Es, Fr & De

GET BOOK

Book Description :

HER2 (ErbB-2) is a member of the human epidermal growth factor receptor tyrosine kinase family which is involved in the regulation of cell proliferation, survival and differentiation. Soon after its discovery, HER2 was shown frequently to be overexpressed in breast cancer and was associated with a worse prognosis. It was identified as a target for drug development and molecular cloning of the gene and expression in cell lines provided a vehicle for the selection of HER2-specific antibodies. The monoclonal antibody trastuzumab is the first HER2-targeting drug approved for cancer treatment. By significantly extending the time to disease progression and overall survival of patients, it has become established in all treatment lines of early and metastatic HER2-positive breast cancer, as well as in HER2-positive advanced metastatic gastric or gastroesophageal junction cancer. Combination of trastuzumab with pertuzumab, a second antibody binding to a distinct epitope on HER2 which implies a different mode of action, took the treatment of HER2-positive metastatic breast cancer to the next level of success. Finally, trastuzumab emtansine is an antibodydrug conjugate that retains all pharmacodynamic activities of trastuzumab and delivers a toxic maytansinoid directly to the tumour cells. Current clinical results indicate that trastuzumab emtansine may be more efficacious and less toxic than trastuzumab plus chemotherapy, and further improvement is expected in combination with pertuzumab.

Testing for HER2 Positive Breast Cancer

Testing for HER2 Positive Breast Cancer Book
Author : Technology Assessment Unit
Publisher : Unknown
Release : 2006
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Testing for HER2 Positive Breast Cancer book written by Technology Assessment Unit, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.